Coherus Oncology, Inc.

This early-stage study tests a new drug called CHS-114 in people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein on certain immune cells to help the body fight cancer. About 87 participants will receive the drug alone or …

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can shrink tumors or slow cancer growth in people with nasopharyngeal cancer that has come back or spread. About 100 adults who have not had prior treatment for…

This early-phase study tests whether a new drug, CHS-114, combined with the immunotherapy toripalimab (and possibly other standard treatments) is safe and can shrink tumors in people with advanced or metastatic solid tumors. About 154 adults whose prior treatments have stopped wo…